Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aspreva, Galenica deal

GALN will acquire ASV for US$26 per share, or about US$915 million in cash. The deal is a 16% premium to ASPV's close

Read the full 231 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE